Discussion 'Myeloma'
Multiple Myeloma: Minimal Residual Disease Testing as an End Point Treatment
Most multiple myeloma patients, even those in complete response, may show signs of relapse at some point of time. So, testing and quantifying Minimal Residual Disease (MRD) has become essential to obtain better prognostic correlations. Researchers believe that MRD testing…
The MMRF Precision Medicine Model – How Close to Multiple Myeloma Cure Are We?
The MMRF has built a unique model that provides the only end-to-end solution in cancer research. This model is based on three interrelated pillars fueled by data generation and integration; collaboration and discovery; and accelerating clinical trials. Integrating this model…
Immunotherapy Advances in Multiple Myeloma
Recent years have seen the emergence of immunotherapy as a leading form of treatment for multiple myeloma. New strategies such as monoclonal antibody therapies. antibody-drug conjugates, immune checkpoint therapy, adoptive cell therapies such as natural killer cells, marrow infiltrating lymphocytes,…
Nonsecretory Multiple Myeloma: New Options in Assessment and Treatment
Hallmark of most multiple myeloma cases is the persistent production of some form of immunoglobulins, a phenomenon that brings the disease to attention. However, there is a subset of multiple myeloma patients who do not secrete immunoglobulin or its component…
High Risk Myeloma Treatment Options
Myeloma is classified as high-risk based on presence of cytogenetic abnormalities and poor treatment outcomes. Despite many new drugs and drug combinations being approved, long term benefits for high risk multiple myeloma patients is less clear. We continue our discussion…